Investor Relations

Latest Presentation

Corporate Presentation

Latest Financial Results

FY 2022

Fiscal Year Ended Aug 31, 2022

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2022

Company Overview

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and over 50 patents pending worldwide.

Stock Snapshot

IR Contacts

Headquarters

Lexaria Bioscience Corp.
740 McCurdy Road
Suite 100
Kelowna, BC V1X 2P7
Canada

Investor Relations

IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com

Transfer Agent

Computershare Investor Services Inc.
T: 800-564-6253
https://www.computershare.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Back to the top